Clinical trial · Observational
Predictive Factors of Pelvic Magnetic Resonance in the Response of Arterial Embolization of Uterine Leiomyoma
NCT01468402CI-TRIAL-00005749completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine predictive factors in the pelvic magnetic resonance in the response of arterial embolization of uterine leiomyoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Exposure to Magnetic Field | — | UNRESOLVED | — |
| Uterine Leiomyoma | Uterine Corpus Leiomyoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnetic Resonance Image | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Magnetic Resonanse Image
- description
- The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroid, and their location in the myometrium was classified. Perfusion and the characterization of the T2 signal were also evaluated.
- interventionNames
- Procedure: Magnetic Resonance Image
Primary outcomes (1)
- measure
- Leiomyoma reduction in patients who underwent uterine artery embolization
- timeFrame
- One month before(baseline) and six month after the embolization
- description
- Use the magnetic resonanse to evaluate factors that predicted leiomyoma reduction in patients who underwent uterine artery embolization
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * ultrasound diagnosis of uterine leiomyoma * presence of symptoms (menorrhalgia and/or pelvic pain) * indication for UAE(the desire to keep the uterus and/or contraindications for surgery). Exclusion Criteria: * malignant genital neoplasms * pelvic inflammatory disease * allergy to iodinated contrast * coagulopathy, renal failure * vasculitis * pelvic irradiation * pregnancy * subserosal leiomyoma with a pedicle smaller than 50% of diameter of the fibroid.
References
Publications (2)
- BACKGROUNDAffonso BB, Nasser F, de Jesus Silva SG, Silva MC, Zlotnik E, de Lorenzo Messina M, Baracat EC. [Strategies for reduction of exposure to ionizing radiation in women undergone to uterine fibroid embolization]. Rev Bras Ginecol Obstet. 2010 Feb;32(2):77-81. Portuguese. PMID 20305945
- BACKGROUNDNasser F, Affonso BB, de Jesus-Silva SG, Coelho Dde O, Zlotnik E, Messina Mde L, Baracat EC. [Uterine fibroid embolization in women with giant fibroids]. Rev Bras Ginecol Obstet. 2010 Nov;32(11):530-5. doi: 10.1590/s0100-72032010001100003. Portuguese. PMID 21271163